FDA Drug Approvals, Dermatology — 2020 Midyear Review

August 14, 2020

Dupixent (dupilumab) - Indicated for moderate-to-severe atopic dermatitis not adequately controlled with topical prescription therapies or when those therapies are not advisable in children aged 6 years or older.

Jublia (efinaconazole) - Indication for onychomycosis expanded to include children as young as 6 years.

Taltz (ixekizumab) - Indication for plaque psoriasis expanded to include children aged 6 years or older.

Eucrisa (crisaborole topical) - Indicated for mild-to-moderate atopic dermatitis in infants and children aged 3 months or older.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: